Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,892,960
  • Shares Outstanding, K 211,040
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 104,220 K
  • 36-Month Beta 0.81
  • Price/Sales 18.89
  • Price/Cash Flow 105.86
  • Price/Book 11.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.60 +2.33%
on 11/21/17
117.95 -16.19%
on 10/31/17
-15.01 (-13.32%)
since 10/24/17
3-Month
96.60 +2.33%
on 11/21/17
140.11 -29.45%
on 08/31/17
-24.79 (-20.17%)
since 08/24/17
52-Week
96.60 +2.33%
on 11/21/17
153.15 -35.46%
on 03/15/17
-7.77 (-7.44%)
since 11/23/16

Most Recent Stories

More News
Today's Research Reports on Trending Tickers: Incyte Corporation and Repros Therapeutics Inc.

NEW YORK, NY / ACCESSWIRE / November 21, 2017 / U.S. markets edged higher Monday as investors focus shifted back towards corporate earnings and potential tax cuts. The Dow Jones Industrial Average gained...

RPRX : 0.44 (-6.38%)
INCY : 99.03 (+0.03%)
Incyte (INCY) Initiates Essential Thrombocythemia Trial

Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

CORT : 17.51 (-1.35%)
SCMP : 10.65 (+2.40%)
INCY : 99.03 (+0.03%)
NVS : 85.12 (+0.76%)
Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global - Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Barracuda Networks, Inc. (NYSE:CUDA),...

CUDA : 23.68 (+0.72%)
FET : 13.65 (+0.74%)
AXAS : 2.10 (+1.94%)
VRTX : 147.31 (+0.18%)
INCY : 99.03 (+0.03%)
SPGI : 163.83 (+0.37%)
Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi(R)) for the Treatment of Essential Thrombocythemia

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the RESET pivotal trial evaluating ruxolitinib (Jakafi(R)) compared to anagrelide for the treatment...

INCY : 99.03 (+0.03%)
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View

AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.

AZN : 33.83 (-0.06%)
JNJ : 137.57 (+0.20%)
MRK : 54.39 (+0.04%)
INCY : 99.03 (+0.03%)
Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed

If you want a Stock Review on IMGN, INCY, INFI, or INSM then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Ahead of today's trading session, DailyStockTracker.com...

IMGN : 6.05 (+3.95%)
INCY : 99.03 (+0.03%)
INFI : 2.06 (unch)
INSM : 30.68 (+1.79%)
Featured Company News - Alnylam Shares Positive Preliminary Results from Ongoing Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1

Research Desk Line-up: Incyte Post Earnings Coverage

ALNY : 132.75 (+0.32%)
INCY : 99.03 (+0.03%)
ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that patients with moderate-to-severe rheumatoid arthritis (RA) treated with baricitinib reported greater improvements...

LLY : 83.99 (+0.37%)
INCY : 99.03 (+0.03%)
Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

AZN : 33.83 (-0.06%)
LLY : 83.99 (+0.37%)
INCY : 99.03 (+0.03%)
NVS : 85.12 (+0.76%)
More Than 30 Abstracts Highlighting Data from Incyte's Portfolio Accepted for Presentation at the 59th Annual ASH Meeting

Incyte Corporation (Nasdaq:INCY) announces that more than 30 abstracts including data from its clinical development programs for Jakafi(R) (ruxolitinib), JAK1, PI3K, PIM and BRD will be presented...

INCY : 99.03 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Key Turning Points

2nd Resistance Point 101.16
1st Resistance Point 100.08
Last Price 99.03
1st Support Level 98.10
2nd Support Level 97.20

See More

52-Week High 153.15
Fibonacci 61.8% 131.55
Fibonacci 50% 124.88
Fibonacci 38.2% 118.20
Last Price 99.03
52-Week Low 96.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart